Evaluation in the Treatment of Neuropathic Pain Post Breast Surgery
Status:
Recruiting
Trial end date:
2023-03-19
Target enrollment:
Participant gender:
Summary
Breast cancer is the most common cancer in women in Europe. Therefore, breast cancer has
become a chronic disease and patients need to learn to live with it as well as with the
adverse effects related to the disease itself or to the therapies used.
As noted in the third "Plan cancer", pain is a major criterion in the quality of life of
patients treated for breast cancer.
Neuropathic pain was defined in 2011 by the international Association for the Study of Pain
(I.A.S.P.) as the direct result of a lesion or disease affecting the somato-sensory system.
Surgical treatment is often the first treatment of breast cancer. It can be conservative by
performing a partial mastectomy (lumpectomy or quadrantectomy) or non-preservative by total
mastectomy.
Intercostobrachial neuralgia (NICB) or Post mastectomy painful Syndrome (MPRR) was first
described by Wood in 1978 as "chronic pain beginning immediately or early after a mastectomy"
Or a lumpectomy affecting the anterior thorax, armpit and/or arm in its upper half. These
post-surgical pains are related to a lesion of the nerves in the breast area.
In particular, the intercostobrachial nerve can be severed, stretched or crushed during
surgery.
Post-operative neuropathic pain in patients with breast cancer is underdiagnosed either by
general practitioner or in a specialized environment.
The diagnosis of neuropathic pain is performed during examination and clinical examination.
Several scales allow to detect neuropathic pain but only the DN4 is recognized to be the most
specific and sensitive scale.
Patients do not always express this pain. They do not always reconcile with the surgery.
Either because the pain occurs a long time after the surgery, or they find it normal to get
hurt. These diagnostic difficulties cause a delay in setting up a suitable analgesic
treatment.
However, neuropathic pain responds poorly to common analgesics. Diagnosis, evaluation and
early management of neuropathic pain are a priority in order to avoid their chronicization,
to improve the quality of life of patients with breast cancer and to enable them to return to
work quickly.
We therefore assume that the diagnosis of early neuropathic pain at 2 months of surgery
associated with initiation of appropriate topical treatment without the systemic effects of
conventional oral treatments, would reduce the incidence of Chronic neuropathic pain 6 months
after surgery.